| CASE REPORT |
|
| Year : 2021 | Volume
: 5
| Issue : 4 | Page : 185-191 |
|
|
Management of moderate cases of COVID-19 through treatment protocol of Ministry of AYUSH: A case series
Meenakshi Sharma1, Sisir Kumar Mandal2, Shagufta Raahat1, Ankita Sunil Pawar1, Shalini Rai1, Anand More1, Tanuja Nesari1
1 All India Institute of Ayurveda, New Delhi, India
2 Vikriti Vigyan, IMS, BHU, Varanasi, Uttar Pradesh, India
Correspondence Address:
Shalini Rai
All India Institute of Ayurveda, New Delhi
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/jras.jras_23_21
|
|
|
The global resurgence of coronavirus 2 (SARS-CoV-2) has severely affected the medical infrastructure, posing a serious public health concern. The present case series documents the successful management of four moderate cases of confirmed coronavirus disease (COVID-19) based on the Ayurveda approach without any adverse effects and any post-COVID presentation. A retrospective analysis of four patients with moderate COVID-19 symptoms was conducted in this study at the All India Institute of Ayurveda. The patients were between the age of 23 and 38 years, were diagnosed as COVID-19 positive through a rapid antigen test (RAT), in July–August 2020, and were managed through Ayurveda interventions. The interventions include Ayush Kwath (10 g twice a day) and Sanshamani Vati (500 mg thrice a day) along with dietary restrictions and nonpharmacological suggestions. The therapeutic interventions were carried out for 7 days. Symptomatic assessment was done every day telephonically, and RAT was conducted after 7 days. Post-COVID complications were assessed in individual cases during the follow-up period (3 months after the completion of treatment). Complete relief in symptoms was observed within 6–7 days in all the cases. No side effects or adverse drug reactions were noticed both during and after the treatment. No post-COVID complications were observed in the four studied cases. The case series suggests that timely Ayurveda intervention has very good potential not only in treating mild-to-moderate patients of COVID-19 infection but also in preventing the post-COVID complications. It could also have a role in reducing the burden of a patient’s turning into a severe category or with complications. However, large-scale randomized controlled trials are required to further validate the same. |
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
